MGMT

Across TCGA pan-cancer cohorts, MGMT mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MGMT data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MGMT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MGMT expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where MGMT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.826	0.562	.004	19	view →
PDAC	DFS	Median	All	0.854	0.683	.011	14	view →
HNSC	OS	Median	IV	0.584	0.820	.014	13	view →
GBM	OS	Tertile	All	0.401	0.586	.021	10	view →
UCEC	OS	Tertile	III,IV	0.305	0.807	.017	8	view →
COAD	DFS	Median	III,IV	1.000	0.846	.049	6	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	6	view →
LSCC	DFS	Quartile	All	0.964	0.883	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MGMT–LUAD (DFS)

Open the LUAD breakdown →